<prompt> Answer this question truthfullyWhat is the reason for conducting screening for cardiomyopathy in patients with noncompaction?  <response>: <reason> Some highly specialized centers do offer genetic screening. Several potential genetic abnormalities have been identified:The gene that encodes for alpha-dystrobrevin . This is a dystrophin-associated protein which has been mapped to chromosome 18q12. The role of this protein is to preserve the structural integrity of the muscle membrane. An X-linked genetic defect which involves a mutation in the gene G4.5 TAZ of the Xq28 chromosome region a gene which encodes for tafazzin, the same region of the chromosome involved in several myopathies with cardiac involvement are located. These include Barth syndrome , Emery-Dreifuss muscular dystrophy, and myotubular myopathy. As a result, some patients with NCC may have features of Barth syndrome. Mutations of the ryanodine receptor 2 gene RyR2 as has been seen in patients with arrhythmogenic right ventricular dysplasia. Deletions of the FKBP12 gene result in noncompaction in the mouse . Knockout of the Peg1 gene has been associated with NCC in the mouse . LMNA mutations Abnormalities of transcription factors such as NKX2.5 and TBX5. Abnormalities of 11p15 as suggested in a GWAS analysis. 22q11 deletion Distal 5q deletion involving the CSX gene 